ロード中...
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
Introduction: Plasma androgen receptor (AR) copy number (CN) status identifies castration-resistant prostate cancer (CRPC) patients with worse outcome on abiraterone/enzalutamide. However, the impact of AR CN changes on clinical outcome in CRPC is unknown. Materials and Methods: Plasma samples from...
保存先:
| 出版年: | Front Oncol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7542981/ https://ncbi.nlm.nih.gov/pubmed/33072600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.567809 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|